###begin article-title 0
###xml 42 45 42 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 22 27 <span type="species:ncbi:9606">human</span>
A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
Platelet aggregation may contribute to the pathogenesis of systemic sclerosis: following activation, platelets release significant amounts of serotonin - which promotes vasoconstriction and fibrosis, and further enhances aggregation. The C+1354T polymorphism in the exonic region of the serotonin 2A receptor gene determining the His452Tyr substitution was associated with blunted intracellular responses after serotonin stimulation, and may have a role in susceptibility to scleroderma.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 171 174 171 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 339 342 339 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 439 442 439 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 446 450 446 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452 </sup>
###xml 457 460 457 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 464 468 464 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452 </sup>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
One hundred and fifteen consecutive systemic sclerosis patients and 140 well-matched healthy control individuals were genotyped by sequence-specific primer-PCR for the His452Tyr substitution of the serotonin 2A receptor gene, and associations were sought with scleroderma and its main clinical features. The functional relevance of the His452Tyr substitution was also assessed by evaluating the aggregation of platelet-rich plasma from His452/His452 and His452/Tyr452 healthy individuals after stimulation with adenosine diphosphate +/- serotonin.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 140 142 140 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 317 319 317 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 346 349 346 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 353 357 353 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452 </sup>
###xml 453 456 453 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 460 464 460 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452 </sup>
###xml 543 545 539 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 584 586 580 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
The T allele of the C+1354T polymorphism was underrepresented in scleroderma patients compared with control individuals (5.2% versus 12.4%, P < 0.001, chi-square test and 1,000-fold permutation test) and its carriage reduced the risk for systemic sclerosis (odds ratio = 0.39, 95% confidence interval = 0.19 to 0.85, P < 0.01). Platelets from His452/Tyr452 healthy subjects more weakly responded to serotonin stimulation compared with platelets from His452/His452 individuals (3.2 +/- 2.6-fold versus 9.6 +/- 8.6-fold increase in aggregation, P = 0.017 by Kolmogorov-Smirnov test and P = 0.003 after correction for baseline adenosine diphosphate-induced aggregation values).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 7 10 7 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
The His452Tyr substitution may influence susceptibility to systemic sclerosis by altering platelet aggregation in response to serotonin.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
Systemic sclerosis (SSc) is a complex connective tissue disease characterised by fibrosis of the skin and internal organs, widespread vasculopathy and abnormalities of the immune system [1]. Whilst the deposition of collagen is the ultimate hallmark of the disease [2], vascular injury and activation are primary events in the pathogenesis of SSc that may sustain the fibrotic process from the earliest phases of the disease [2,3].
###end p 11
###begin p 12
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 186 187 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 644 646 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 822 824 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 715 723 <span type="species:ncbi:9606">patients</span>
Amongst the vascular alterations described in SSc patients, perturbations in platelet homeostasis have long been recognised [4]. Platelets from SSc patients show an activated phenotype [5,6] and highly respond to a variety of aggregating stimuli [7], releasing biomolecules with vasoactive, inflammatory, mitogenic and profibrotic properties [8]. Platelets are a rich source of serotonin (5-hydroxitrpitamine (5-HT)) [9] - a powerful mediator with a wide array of functions, ranging from vasoconstriction in damaged vessels [10], mitogenesis of vascular smooth muscle cells [11] and fibroblasts [12], to the activation of platelets themselves [13,14]. Increased concentrations of 5-HT were found in plasma from SSc patients [15], and the depletion of intraplatelet 5-HT concentrations was also observed in these subjects [16], reflecting both the release of 5-HT from intracellular stores and platelets' persistent activation.
###end p 12
###begin p 13
###xml 92 94 92 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 102 103 102 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 174 176 174 176 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 317 320 317 320 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 706 709 706 709 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 753 756 753 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 815 817 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 923 925 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1066 1068 1066 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1199 1202 1199 1202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 1220 1222 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
The 5-HT functions are mediated by a superfamily of seven related G-coupled receptors (5-HTR1 to 5-HTR7) [17], but it is the interaction with the serotonin 2A receptor (5-HTR2A) that accounts for most of the detrimental profibrotic, vasoconstrictive, mitogenic and proaggregating activities of 5-HT [10-14]. The 5-HTR2A gene is located at 13q14-q21, and several single nucleotide polymorphisms (SNPs) have been identified within this region, a few of which determine amino acid substitutions and may thus be relevant from a functional point of view [18]. Amongst these substitutions, one of the most well characterised is the nonconservative C/T transition at position +1,354 of the third exon of the 5-HTR2A gene (C+1354T, rs6314) that determines a His452Tyr substitution in the C-terminal region of the receptor [19]. This relatively abundant substitution has variedly been associated with several psychiatric disorders [20] and may influence 5-HT responses by destabilising the intracellular signal, reducing the activation of G-dependent phospholipases C and D [21]. These events may account for the described reduced mobilisation of intracellular calcium of platelets from subjects with the His452Tyr substitution [22], and may eventually lead to a blunted platelet aggregation.
###end p 13
###begin p 14
###xml 98 101 98 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 320 323 320 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
In the present study we first explored a possible association between the C+1354T SNP of the 5-HTR2A gene and SSc, and we then further clarified its functional role by evaluating platelet aggregation in response to the costimulation with ADP and 5-HT [14] in healthy subjects with either one of the variants of the 5-HTR2A gene.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient selection
###end title 16
###begin p 17
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 470 472 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 650 652 650 652 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 383 390 <span type="species:ncbi:9606">patient</span>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
###xml 547 555 <span type="species:ncbi:9606">patients</span>
One hundred and fifteen consecutive unrelated Italian SSc patients referred to our outpatient clinic were included. All of the patients fulfilled the classification criteria proposed by the American College of Rheumatology [23], and were categorised as having limited cutaneous SSc or diffuse cutaneous SSc according to LeRoy and colleagues [24]. Disease onset was determined by the patient's recall of the first non-Raynaud symptom clearly attributable to scleroderma [25]. The patients' autoantibody profile was also determined by reviewing the patients' medical records. Antinuclear antibodies were determined by indirect immunofluorescence on Hep2 cells (Kallestad, Chaska, MN, USA) using a standardised technique [26]. Extractable nuclear antigens were determined by a commercial ELISA (Diamedix, Miami, FL, USA). The presence of a reduced forced vital capacity (<70% of predicted), of a reduced diffusing capacity for carbon monoxide (<70% of predicted) or of an increased right-ventricular systolic pressure on echo (>/= 40 mmHg) was also assessed.
###end p 17
###begin p 18
One hundred and forty healthy ethnically matched, sex-matched and age-matched subjects were also included as control individuals (case-to-control ratio, 1:2).
###end p 18
###begin p 19
###xml 11 19 <span type="species:ncbi:9606">patients</span>
All of the patients and all of the controls gave their written consent for the present research. The protocols of the study as well as of the functional study described below were approved by the ethic committee of our institution, and are in compliance with the Declaration of Helsinki.
###end p 19
###begin title 20
###xml 33 36 33 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 40 43 40 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
Sequence-specific primer-PCR for 452His/452Tyr
###end title 20
###begin p 21
###xml 229 232 229 232 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 355 358 355 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 544 545 544 545 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 568 572 <span type="species:ncbi:9319">Euro</span>
###xml 578 582 <span type="species:ncbi:9319">Euro</span>
Ten millilitres of blood were collected into tubes containing sodium citrate. Genomic DNA was isolated with the DNA Isolation Kit for Mammalian Blood (Roche Diagnostics, Indianapolis, IN, USA). To detect the C+1354T SNP, the 5HTR2A gene was amplified using PCR. In brief, a set of primers was designed to encompass the C+1354T polymorphic site in the 5HTR2A gene (forward primer, 5'-AGCCAACTTCAAATGGGACA-3' and reverse primer, 5'-CACACACAGCTCACCTTTTCA-3'). The PCR reaction was performed using 100 ng genomic DNA, 10 pM each primer, 1.5 mM MgCl2, 2.5 mM dNTPs and 1 U Euro Taq (Euro Clone, Milano, Italy) in a final volume of 25 mul. PCR amplification was initiated at 96degreesC for 5 minutes and was performed for 40 cycles, each consisting of 30 seconds at 96degreesC, 45 seconds at 58degreesC and 45 seconds at 72degreesC. A final elongation step of 5 minutes at 72degreesC was added.
###end p 21
###begin title 22
Sequencing
###end title 22
###begin p 23
All of the PCR products were sequenced. Prior to sequencing, the unincorporated dNTPs and primer were removed by ExoSAP-IT (USB Corporation, Cleveland, OH, USA) at 37degreesC for 15 minutes, after which the enzymes were deactivated by incubation at 80degreesC for 15 minutes. Samples were sequenced in both directions on an Applied Biosystems 3100 Genetic Analyzer using the Big-Dye Terminator Cycle Sequencing Reaction Kit (Applied Biosystems, Foster City, CA, USA). The cycling conditions were 25 cycles of denaturation at 96degreesC for 10 seconds, annealing at 50degreesC for 5 seconds and extension at 60degreesC for 4 minutes.
###end p 23
###begin title 24
Platelet aggregation
###end title 24
###begin p 25
###xml 19 22 19 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 26 29 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 37 40 37 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 44 47 44 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 309 311 309 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 406 408 406 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 818 819 811 812 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 830 831 823 824 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Blood samples from 452His/452Tyr and 452Tyr/452Tyr healthy nonsmoker individuals were obtained for the functional study; none of these subjects was receiving steroids or antiaggregation therapy. Whole blood, anticoagulated with sodium citrate (final concentration, 3.8%), was immediately centrifuged at 130 x g for 15 minutes in order to obtain platelet-rich plasma. A subsequent centrifugation at 1,050 x g for 15 minutes allowed one to obtain platelet-poor plasma, used to set the 100% light transmission of the instrument. Then 250 mul platelet-rich plasma was warmed at 37degreesC for 3 minutes, and the agonist was added. Platelet aggregation was performed on a Chrono-Log Aggregometer (Mascia-Brunelli, Milano, Italy) with ADP (Sigma-Aldrich Corp, Milano, Italy) in a plain Tyrode's solution containing 2 mM CaCl2, 1 mM MgCl2, 0.1% dextrose, 0.35% BSA, 0.05 U/ml apyrase, pH 7.35, at a final concentration of 1 muM, or with ADP + 5-HT (Sigma-Aldrich Corp.) both at a 1 muM final concentration. Platelet aggregation was recorded for 3 minutes and the maximum light transmission in this period was measured. The response to 5-HT was then calculated as the fold increase in 5-HT-induced aggregation with respect to the aggregation observed after stimulation with ADP alone.
###end p 25
###begin p 26
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 557 558 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
In the present work the decision was made not to replicate the functional study in SSc patients. This decision was mainly due to different reasons. Firstly, all of our patients were being treated with a combination of drugs that may alter platelet function (for example, low-dose aspirin, nifedipine, chronic intravenous iloprost), and thus it would have been unethical to interrupt their ongoing therapy. Secondly, SSc platelets show an activated phenotype that that would have been a significant confounding factor in the analysis of platelet function [5-7].
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin title 28
Association study
###end title 28
###begin p 29
###xml 134 142 <span type="species:ncbi:9606">patients</span>
The distribution of the C+1354T genotypes was tested for Hardy-Weinberg equilibrium with the goodness-of-fit chi-squared test both in patients and in control individuals.
###end p 29
###begin p 30
The distribution of the C+1354T genotypes and alleles between control individuals and SSc subjects was tested by the chi-squared test or Fisher's exact test when necessary. Odds ratios and their relative 95% confidence intervals were also calculated from 2 x 2 contingency tables. Statistical significance was also evaluated using a 1,000-fold permutation test.
###end p 30
###begin p 31
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Genetic-association studies might be flawed by the possibility of false-positive results, even in the presence of statistically significant findings - that is, according to the definition of Wacholder and colleagues [27], the false-positive report probability (FPRP). The FPRP values are calculated by the following formula: FPRP = 1/{1 + [pi/(1 - pi)] [(1 - beta)/alpha]}, where pi is the prior probability that the association is true, alpha is the type I error probability and beta is the type II probability to detect the association under the experimental conditions.
###end p 31
###begin p 32
###xml 54 56 50 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 172 175 167 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 306 315 301 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 331 333 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
In the present context, alpha was set to the observed P value while pi was set from 0.001 up to relatively high values (0.5 - 1), given that only five SNPs within the 5-HTR2A gene determine amino acid substitutions and may thus be functionally relevant, and the C+1354T SNP indeed alters platelet function in vitro (see reference [22] and the results below).
###end p 32
###begin p 33
###xml 76 78 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 179 182 176 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 186 189 183 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 325 327 318 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Finally, the statistical power (1 - beta) was calculated by the PS Program [28], and it was defined as the power to detect an odds ratio of 1.5, 1.75 or 2 for the carriers of the 452His/452Tyr substitution and to detect an odds ratio of 1 for the homozygote with the common variant, with an alpha level equal to the observed P value.
###end p 33
###begin p 34
###xml 248 250 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 363 365 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
The FPRP values for the present study were then reported in a table with the corresponding pi and odds ratio values; FPRP values < 0.5 are then highlighted. These values are considered adequate in small exploratory studies on genetic associations [27] - given that some estimates of the overall FPRP in the molecular epidemiology literature have been up to 0.95 [29].
###end p 34
###begin title 35
Functional study
###end title 35
###begin p 36
###xml 36 39 36 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 43 46 43 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 54 57 54 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 61 64 61 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
The 5-HT-to-ADP aggregation rate in 452His/452His and 452His/452Tyr healthy subjects was compared by the nonparametric Kolmogorov-Smirnov test and was then verified by linear regression. As platelet-induced aggregation displays a ceiling effect, the magnitude of the dependent variable (5-HT-to-ADP aggregation ratio) may be correlated with the variance of baseline (ADP-induced) aggregation, thus violating the assumption of homoscedasticity [30]. Linear regression was thus conducted by the weighted least-squares analysis procedure, with the ADP-induced aggregation as the weight variable and with gender as an additional covariate.
###end p 36
###begin p 37
###xml 118 120 118 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
All of the statistical procedures were carried out with the SPSS version 15.0 software (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered significant.
###end p 37
###begin p 38
Continuous values are expressed as the mean +/- standard deviation - except for skewed distributions (skewness <-2 or skewness >2), where the median and interquartile range are reported.
###end p 38
###begin title 39
Results
###end title 39
###begin p 40
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
The demographic and clinical characteristics of the patients are reported in Table 1. The genotypes of the C+1354T SNP respected the Hardy-Weinberg equilibrium both in patients and in control individuals. The overall minor allele frequency was 0.092.
###end p 40
###begin p 41
Demographic and clinical characteristics
###end p 41
###begin p 42
###xml 18 20 18 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
Data presented as n (%) or as the mean +/- standard deviation.
###end p 42
###begin title 43
Association study
###end title 43
###begin p 44
###xml 21 22 21 22 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 42 45 42 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 49 52 49 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 94 97 94 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 101 104 101 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 217 219 215 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 252 254 250 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 346 348 342 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 380 382 376 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 465 467 461 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 478 480 474 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 539 542 535 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 546 549 542 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 557 560 553 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 564 567 560 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 643 646 639 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 650 653 646 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 729 731 725 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 170 178 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
As reported in Table 2, the CT genotypes (452His/452Tyr heterozygosity) and the TT genotypes (452Tyr/452Tyr homozygosity) of the C+1354T SNP were underrepresented in SSc patients compared with control individuals (chi2 = 7.102, two degrees of freedom, P = 0.011). Similarly, a decreased frequency of the T allele was observed in SSc patients (chi2 = 7.308, one degree of freedom, P < 0.001). All of the results were confirmed after the 1,000-fold permutation test (P < 0.05 and P < 0.001 for genotypes and alleles, respectively). Overall, 452His/452Tyr and 452Tyr/452Tyr individuals had a threefold reduction in the risk for SSc compared with 452His/452His individuals (odds ratio = 0.39, 95% confidence interval = 0.19 to 0.85, P < 0.01).
###end p 44
###begin p 45
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Genotype and allele distribution of the C+1354T single nucleotide polymorphism in patients with systemic sclerosis and in matched control individuals
###end p 45
###begin p 46
###xml 18 20 18 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 25 27 25 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 37 39 37 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Data presented as n (%).*P < 0.05. **P < 0.01 (chi-square test).
###end p 46
###begin p 47
###xml 55 58 55 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 62 65 62 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
The FPRP values of the association between SSc and the 452His/452Tyr substitution are reported in Table 3 with highlighted noteworthiness values at the 0.5 level.
###end p 47
###begin p 48
False-positive report probabilities under different scenarios
###end p 48
###begin p 49
###xml 302 305 302 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 309 312 309 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 342 345 342 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
False-positive report probability values are presented for the association between the C+1354T single nucleotide polymorphism and systemic sclerosis in our population. Different ranges of values are reported in relation to the prior probability values and the power to detect different odds ratios for 452His/452Tyr individuals compared with 452His/452His subjects, with alpha = 0.009. Data in italics are reported noteworthy false-positive report probability values at the 0.5 level.
###end p 49
###begin p 50
###xml 207 210 207 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
Robust associations with clinical variables were difficult to calculate owing to the low prevalence of the rarer allele of the C+1354T SNP in SSc patients; however, from an exploratory point of view, the His452Tyr substitution was not associated with any of the following: the disease subset, the anticorpal status, age at the onset of the disease, past history of digital ulcers, the forced viral capacity, the diffusing capacity for carbon monoxide or the right systolic ventricular pressure.
###end p 50
###begin title 51
Platelet aggregation
###end title 51
###begin p 52
###xml 42 45 42 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 49 52 49 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 83 86 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 90 93 90 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 473 474 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
Platelets from 15 healthy subjects (eight 452His/452His homozygous subjects, seven 452His/452Tyr heterozygous subjects) had poor aggregating responses after stimulation with ADP alone (median, 11.8%; interquartile range, 5.4% to 25% light transmission). Aggregating responses were markedly increased after costimulation with 5-HT and ADP (median, 3.8-fold increase; interquartile range, 2.9-fold to 8.6-fold) with respect to the stimulation observed with ADP alone (Figure 1). These data are consistent with previous studies reported in the literature [14].
###end p 52
###begin p 53
Platelet aggregation induced by ADP and serotonin. Left panel: aggregation induced by 1 muM ADP + 1 muM buffer solution (plain Tyrode's solution (PT)). Right panel: aggregation induced by 1 muM ADP + 1 muM serotonin (5-HT). The ratio between the two highest light transmission percentages is the 5-HT-to-ADP response ratio (in the example, 68.5/21.2 = 3.23-fold increase).
###end p 53
###begin p 54
###xml 105 108 105 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 112 115 112 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 135 138 135 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 142 145 142 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 166 169 166 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 173 176 173 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 258 261 258 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 265 268 265 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 350 352 346 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 400 403 396 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 596 599 592 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 628 631 624 627 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 689 690 685 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 692 694 688 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 761 762 757 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 762 764 758 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 918 921 914 917 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 977 980 973 976 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 1017 1020 1013 1016 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
The ADP-induced baseline aggregation, age, platelet count and gender distribution did not differ between 452His/452His individuals and 452His/452Tyr individuals. The 452His/452Tyr heterozygous subjects had blunted responses to 5-HT stimulation compared with 452His/452His homozygous subjects (mean, 3.2 +/- 2.6-fold versus 9.6 +/- 8.6-fold increase, P = 0.017). The functional significance of the His452Tyr substitution was better assessed by linear regression analysis, weighted for ADP-induced platelet aggregation; by this procedure, it was confirmed at a highly significant level that the His452Tyr substitution of the 5-HTR2A dampened platelet aggregation in response to 5-HT (Figure 2, P = 0.003). The regression equation of the final model with adjusted R2 = 0.98 had an almost perfect fit: 5-HT-to-ADP-response ratio (fold increase) = 4.995 - (0.019 x ADP-induced aggregation) - (1.148 x gender) - (1.192 x His452Tyr substitution) (where zero represents females and/or 452His, and one represents males and/or 452Tyr).
###end p 54
###begin p 55
###xml 60 63 60 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 67 70 67 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 81 84 81 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 88 91 88 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 320 323 320 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 327 330 327 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 341 344 341 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 348 351 348 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
Serotonin-induced platelet aggregation in subjects with the 452His/452His or the 452His/452Tyr phenotype. Fold increase of serotonin (5-HT)-induced platelet aggregation after correction for baseline ADP aggregation values by the weighted least-squares analysis procedure (see Materials and methods) in subjects with the 452His/452His or the 452His/452Tyr phenotype. Black centre line, median for each dataset; boxes, interquartile range; bars, cases (three box-lengths form the 25th or the 75th percentile).
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 81 82 81 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 389 390 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 637 640 637 640 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
###xml 676 684 <span type="species:ncbi:9606">patients</span>
Owing to the evidence of involvement of vasculopathy in the pathogenesis of SSc [2,3], much research has been carried out to elucidate the role of genetic variants of biomolecules with vascular activities in scleroderma patients [31-37]. Despite the number of studies indicating a role for platelets and the 5-HT system in the onset of or in the maintenance of the vascular damage in SSc [4], however, no genetic research has so far been conducted in this field. The present study was thus undertaken to analyse, for the first time, the distribution and the functional role of a naturally occurring amino acidic substitution of the 5-HTR2A gene in a population of Italian SSc patients.
###end p 57
###begin p 58
###xml 94 97 94 97 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 277 280 277 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 284 287 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 319 322 319 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 326 329 326 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 366 374 366 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 460 463 460 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 492 495 492 495 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
Our results indicate that the C/T transition at position +1,354 of the third exon of the 5-HTR2A gene [19] is associated with a threefold reduction in the risk for SSc. This effect could be linked to a blunted platelet aggregation in response to the serotoninergic stimulus in 452His/452Tyr heterozygotes compared with 452His/452His homozygotes, as indicated by our ex vivo study (Figure 2). This observation is in full accordance with the finding that the His452tyr substitution in the 5-HTR2A gene is accompanied by a reduced mobilisation of platelet intracellular calcium after stimulation with 5-HT [22].
###end p 58
###begin p 59
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 423 424 423 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 425 426 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 740 743 740 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 865 868 865 868 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1130 1133 1130 1133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1093 1099 <span type="species:ncbi:10090">murine</span>
The 5-HT concentrations are increased in plasma samples from SSc [16] as a consequence of platelet activation that follows the binding to collagen type I and type III exposed under the damaged endothelium, which is also favoured by T-dependent immunological mechanisms [4]. It is thus possible to speculate that the carriage of the C+1354T SNP dampens the mechanisms that sustain platelet aggregation and SSc vasculopathy [2,4], once they have been triggered via other biological pathways. This hypothesis would confirm previous findings indicating that 5-HT is more relevant in the maintenance of the vascular phenomena that underlie the pathogenesis of SSc, rather than in determining their onset [38]. We cannot, however, exclude the His452Tyr substitution possibly having a role in SSc susceptibility by acting on different cellular types that express the 5-HTR2A gene (for example, fibroblasts or vascular smooth muscle cells), regardless of its effect on 5-HT-induced platelet aggregation. Indeed, Hazelwood and Sanders-Bush also described a reduced intracellular signalling capacity in murine fibroblasts expressing the His452Tyr substitution after stimulation with 5-HT [21].
###end p 59
###begin p 60
###xml 201 204 201 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 590 592 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1069 1071 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1251 1254 1249 1252 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1305 1308 1303 1306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3A </sub>
###xml 1380 1382 1378 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1383 1385 1381 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
The potential limitations of our study are the relatively small sample size and the lack of a replicate population. We feel confident that the evidence demonstrating the functional relevance of the His452Tyr substitution, however, makes our findings modestly prone to false positive results. The significance of our results can also be gauged considering the FPRP values we obtained under different scenarios (Table 3). Whilst no significant FPRP values were observed for prior probabilities </= 0.01, which were originally advocated as an adequate setting for a gene with functional data [27], it may be argued that these prior probability values, or conversely the FPRP 0.5 threshold, may be too penalising for an exploratory study such as ours. Even if no single point mutation is therefore likely to determine the onset of a multifactorial disease such as SSc, our results indicate that the C+1354T SNP is a suitable SNP for further research in the scleroderma field and that it may be worthy of inclusion in association studies based on a candidate gene approach [39]. Of particular interest would also be the study of epistatic interactions or intermediate quantitative trait analysis between this mutation and other genetic variants of the 5-HT2A gene or other serotonin receptors, such as the 5-HT3A gene that was also found to play a role in the fibrotic process of SSc [40,41]. Finally, the demonstration that the C+1354T SNP is indeed associated with a reduced platelet aggregation after stimulation with 5-HT may have practical implications besides SSc - that is, in other diseases where the serotoninergic system is involved.
###end p 60
###begin title 61
Conclusion
###end title 61
###begin p 62
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 63 65 63 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 181 189 181 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 405 413 <span type="species:ncbi:9606">patients</span>
We provide evidence that the His452Tyr substitution of the 5-HT2Areceptor, determined by the C+1354T SNP of the corresponding gene, is functionally relevant to platelet aggregation in vitro, dampening the responses to the serotoninergic stimulus. The functional relevance of this polymorphism may explain the inverse association (for example, protective effect) we observed in a population of Italian SSc patients. The C+1354T SNP is therefore worth inclusion in a panel of candidate genes for future association studies in the SSc field.
###end p 62
###begin title 63
Abbreviations
###end title 63
###begin p 64
###xml 132 134 132 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 5 11 <span type="species:ncbi:9913">bovine</span>
BSA: bovine serum albumin; ELISA: enzyme-linked immunosorbent assay; FPRP: false-positive report probability; 5-HT: serotonin; 5-HTR2A: serotonin 2A receptor; PCR: polymerase chain reaction; SSc: systemic sclerosis; SNP: single nucleotide polymorphism.
###end p 64
###begin title 65
Competing interests
###end title 65
###begin p 66
The authors declare that they have no competing interests.
###end p 66
###begin title 67
Authors' contributions
###end title 67
###begin p 68
LB was responsible for the study design, manuscript preparation, analysis and interpretation of data, and statistical analysis. MC participated in collection of data, interpretation of data and genetic analysis. MM performed genetic analysis. FC was responsible for manuscript preparation and interpretation of data. AA and GM performed the platelet functional study. RS was responsible for the study design and fundraising.
###end p 68
###begin article-title 69
Clinical aspect of systemic sclerosis (scleroderma)
###end article-title 69
###begin article-title 70
Systemic sclerosis: a prototypic multisystem fibrotic disorder
###end article-title 70
###begin article-title 71
Systemic sclerosis. A vascular perspective
###end article-title 71
###begin article-title 72
Platelet contributions to the pathogenesis of systemic sclerosis
###end article-title 72
###begin article-title 73
Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma
###end article-title 73
###begin article-title 74
Platelet function study in primary Raynaud's phenomenon and Raynaud's phenomenon associated with scleroderma
###end article-title 74
###begin article-title 75
Serotonin induced platelet aggregation in systemic sclerosis
###end article-title 75
###begin article-title 76
Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis
###end article-title 76
###begin article-title 77
###xml 23 28 <span type="species:ncbi:9606">human</span>
Serotonergic status in human blood
###end article-title 77
###begin article-title 78
###xml 17 19 17 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle
###end article-title 78
###begin article-title 79
Mitogenic effect of serotonin on vascular endothelial cells
###end article-title 79
###begin article-title 80
Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter
###end article-title 80
###begin article-title 81
###xml 132 135 132 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 150 157 <span type="species:ncbi:9986">rabbits</span>
Role of 5-hydroxytryptamine in platelet thrombus formation and mechanisms of inhibition of thrombus formation by 5-hydroxytryptamine2A antagonists in rabbits
###end article-title 81
###begin article-title 82
Effects of serotonin on platelet activation in whole blood
###end article-title 82
###begin article-title 83
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon
###end article-title 83
###begin article-title 84
Platelet serotonin in systemic sclerosis
###end article-title 84
###begin article-title 85
Classification and nomenclature of 5-HT receptors: a comment on current issues
###end article-title 85
###begin article-title 86
NCBI Entrez SNP
###end article-title 86
###begin article-title 87
###xml 60 63 60 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Two naturally occurring amino acid substitutions of the 5-HT2A receptor: similar prevalence in patients with seasonal affective disorder and controls
###end article-title 87
###begin article-title 88
###xml 3 6 3 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies
###end article-title 88
###begin article-title 89
###xml 3 6 3 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">452</sup>
###xml 40 43 40 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 30 35 <span type="species:ncbi:9606">human</span>
His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation
###end article-title 89
###begin article-title 90
###xml 73 76 73 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 53 58 <span type="species:ncbi:9606">human</span>
A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization
###end article-title 90
###begin article-title 91
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutics Criteria Committee
###end article-title 91
###begin article-title 92
Scleroderma (systemic sclerosis): classification, subset and pathogenesis
###end article-title 92
###begin article-title 93
Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis
###end article-title 93
###begin article-title 94
Multicenter evaluation study on a new HEp2 ANA screening enzyme immune assay
###end article-title 94
###begin article-title 95
Assessing the probability that a positive report is false: an approach for molecular epidemiology studies
###end article-title 95
###begin article-title 96
PS power and sample size program available for free on the Internet
###end article-title 96
###begin article-title 97
Problems of reporting genetic associations with complex outcomes
###end article-title 97
###begin article-title 98
Interpreting heteroscedasticity
###end article-title 98
###begin article-title 99
Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension
###end article-title 99
###begin article-title 100
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Endothelin axis polymorphisms in patients with scleroderma
###end article-title 100
###begin article-title 101
Hemorheologic profile in systemic sclerosis: role of NOS3 -786T >C and 894G >T polymorphisms in modulating both the hemorheologic parameters and the susceptibility to the disease
###end article-title 101
###begin article-title 102
###xml 174 182 <span type="species:ncbi:9606">patients</span>
Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients
###end article-title 102
###begin article-title 103
###xml 148 156 <span type="species:ncbi:9606">patients</span>
Lack of association of eNOS (G894T) and p22phox NADPH oxidase subunit (C242T) polymorphisms with systemic sclerosis in a cohort of French Caucasian patients
###end article-title 103
###begin article-title 104
Oxygen free radical scavenger enzyme polymorphisms in systemic sclerosis
###end article-title 104
###begin article-title 105
###xml 114 117 114 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">298</sup>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis
###end article-title 105
###begin article-title 106
Serotonin and Raynaud's phenomenon
###end article-title 106
###begin article-title 107
Genetic factors in systemic sclerosis
###end article-title 107
###begin article-title 108
###xml 45 47 45 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Treatment of systemic sclerosis with the 5-HT3 receptor antagonist tropisetron
###end article-title 108
###begin article-title 109
Antagonism of the serotonin pathway - a novel antifibrotic approach?
###end article-title 109

